

Correction: Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy



In the original version of this article (1), there is an error in the Methods section, as well as in Fig. 3A and its accompanying legend. The correct BAC is CTD-2197P5, not RP11-1042H15. Figure 3A has been revised to show CTD-2197P5 in place of RP11-1042H15, and blue shading illustrating the genomic region spanned by this BAC has been adjusted accordingly. The errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

REFERENCE

1. Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T-cell exhaustion averted by concurrent cytotoxic therapy. *Blood Cancer Discov* 2021;2:354–69.

Published first January 11, 2022.

Blood Cancer Discov 2022;3:82

doi: 10.1158/2643-3230.BCD-21-0176

©2022 American Association for Cancer Research